Kiromic Submits IND Application Early

 Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics, today announced the submission of a novel Investigational New Drug (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial that has the potential to be a universal CAR T-Cell therapy for any solid malignancy that expresses the biomarker Iso-mesothelin, with higher efficacy, higher safety, as well as lower manufacturing and distribution costs.

https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter